| Identification | Back Directory | [Name]
NEUROPEPTIDE SF (HUMAN) | [CAS]
192387-39-6 | [Synonyms]
NEUROPEPTIDE SF (HUMAN)
Neuropeptide SF human >=92% (HPLC), solid
Neuropeptide SF(human 11-amino acid fragment)
H-SER-GLN-ALA-PHE-LEU-PHE-GLN-PRO-GLN-ARG-PHE-NH2
Dalargin(wound healing peptide: Afonskaya N.I. Bull.Exp.Biol.Med. 12, 754, 1986) | [Molecular Formula]
C65H94N18O15 | [MDL Number]
MFCD03093437 | [MOL File]
192387-39-6.mol | [Molecular Weight]
1367.55 |
| Chemical Properties | Back Directory | [density ]
1.43±0.1 g/cm3(Predicted) | [storage temp. ]
−20°C
| [form ]
solid
| [pka]
12.03±0.10(Predicted) | [color ]
White to off-white | [Water Solubility ]
Soluble to 1 mg/ml in 10% acetonitrile / sterile water | [Sequence]
Ser-Gln-Ala-Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2 |
| Hazard Information | Back Directory | [Uses]
Neuropeptide SF human augments paraventricular corticotrophin-releasing hormone (CRH) release and increases adrenocorticotropic hormone (ACTH) and corticosterone levels in the plasma. Neuropeptide SF human play a physiologic role in the regulation of such circadian functions as the activity of motor centers and the HPA axis, through the release of CRH[1]. | [storage]
Desiccate at -20°C | [References]
[1] Jászberényi M, et al., The actions of neuropeptide SF on the hypothalamic-pituitary-adrenal axis and behavior in rats. Regul Pept. 2014 Jan 10;188:46-51. DOI:10.1016/j.regpep.2013.11.004 |
|
|